Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.zyduscadila.com | |
Market Cap | 96,553.18 Cr. | |
Enterprise Value(EV) | 95,796.08 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 29.55 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 32.47 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.03 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 187.28 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 5.12 | Calculated using Price: 959.55 |
Dividend Yield | 0.63 | Period Ending 2023-03 |
No. of Shares Subscribed | 100.62 Cr. | 1,006,233,990 Shares |
FaceValue | 1 | |
About Zydus Lifesciences Ltd. | ||
The company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. Innovation is the backbone of the company as it ensures business sustainability through continuous availability of new products for various businesses. |
1 Day |
|
-0.03% |
1 Week |
|
+2.60% |
1 Month |
|
-4.03% |
3 Month |
|
+36.33% |
6 Month |
|
+65.74% |
1 Year |
|
+84.95% |
2 Year |
|
+172.34% |
5 Year |
|
+190.13% |
10 Year |
|
+385.43% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 30.85 | 38.62 | 23.47 | 22.5 | 19.36 | 11.32 | 18.88 | 15.51 | 11.6 | |
Return on Capital Employed (%) | 23.21 | 28.6 | 16.52 | 18.55 | 15.89 | 10.02 | 14.38 | 15.3 | 13.64 | |
Return on Assets (%) | 13.93 | 20.14 | 12.2 | 11.23 | 9.34 | 5.18 | 9.66 | 9.4 | 7.82 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 4,252 | 5,699 | 6,960 | 8,745 | 10,386 | 10,376 | 12,992 | 17,000 | 17,516 | 18,733 | |
Non Curr. Liab. | 1,342 | 736 | 1,903 | 2,122 | 3,491 | 2,854 | 19 | -194 | -725 | -1,116 | |
Curr. Liab. | 3,285 | 3,461 | 5,306 | 6,072 | 7,343 | 8,269 | 7,861 | 7,827 | 5,527 | 4,363 | |
Minority Int. | 169 | 136 | 156 | 191 | 1,293 | 1,335 | 1,937 | 2,054 | 2,173 | 2,208 | |
Equity & Liab. | 9,047 | 10,032 | 14,325 | 17,141 | 22,513 | 22,834 | 22,810 | 26,700 | 24,494 | 24,188 | |
Non Curr. Assets | 4,820 | 5,752 | 8,303 | 8,911 | 14,015 | 14,118 | 14,094 | 14,438 | 14,478 | 14,253 | |
Curr. Assets | 4,227 | 4,280 | 6,022 | 8,201 | 8,498 | 8,715 | 8,716 | 12,095 | 10,008 | 9,935 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 9,047 | 10,032 | 14,325 | 17,141 | 22,513 | 22,834 | 22,810 | 26,700 | 24,494 | 24,188 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 8,651 | 9,427 | 9,377 | 11,905 | 13,166 | 14,253 | 14,404 | 15,110 | 17,237 | 19,024 | |
Other Income | 57 | 117 | 147 | 133 | 209 | 117 | 75 | 391 | 475 | 268 | |
Total Income | 8,709 | 9,543 | 9,524 | 12,038 | 13,374 | 14,370 | 14,479 | 15,501 | 17,712 | 19,293 | |
Total Expenditure | -6,897 | -7,097 | -7,472 | -9,058 | -10,187 | -11,473 | -11,018 | -11,935 | -13,666 | -14,118 | |
PBIDT | 1,811 | 2,446 | 2,051 | 2,980 | 3,187 | 2,897 | 3,460 | 3,565 | 4,047 | 5,175 | |
Interest | -68 | -53 | -63 | -111 | -196 | -342 | -186 | -127 | -130 | -74 | |
Depreciation | -287 | -292 | -373 | -539 | -599 | -697 | -670 | -713 | -723 | -737 | |
Taxation | -259 | -177 | -129 | -564 | -530 | -320 | -194 | -512 | -588 | -794 | |
Exceptional Items | -10 | -3 | 0 | -10 | -364 | -205 | 113 | -604 | -616 | ||
PAT | 1,186 | 1,921 | 1,486 | 1,766 | 1,852 | 1,176 | 2,206 | 2,326 | 2,002 | 2,954 | |
Minority Interest | -38 | -30 | -29 | -35 | -50 | -28 | -51 | -131 | -132 | -111 | |
Share Associate | 43 | 34 | 63 | 47 | 29 | 47 | 46 | 95 | 113 | ||
Other Related Items | 2 | ||||||||||
Consolidated Net Profit | 1,151 | 1,934 | 1,488 | 1,776 | 1,849 | 1,177 | 2,134 | 4,487 | 1,960 | 2,974 | |
Adjusted EPS | 11 | 19 | 15 | 17 | 18 | 11 | 21 | 44 | 19 | 29 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 903 | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,105 | 2,689 | |
Cash Fr. Inv. | -438 | -465 | -864 | -2,872 | -974 | -4,239 | -1,012 | -725 | -1,000 | 1,171 | |
Cash Fr. Finan. | -529 | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,548 | -868 | -4,400 | |
Net Change | -64 | 178 | 95 | 756 | -3 | -1,072 | 391 | 22 | 236 | -540 | |
Cash & Cash Eqvt | 613 | 790 | 837 | 1,593 | 1,590 | 779 | 1,178 | 1,087 | 1,107 | 573 |
Tue, 23 Apr 2024
Loss/Duplicate-Share Certificate-XBRL ZYDUS LIFESCIENCES LIMITED has informed the Exchange about Loss of share certificates |
Tue, 23 Apr 2024
Loss of Share Certificates Zydus Lifesciences Limited has informed the Exchange about Loss of Share Certificates |
Tue, 23 Apr 2024
Press Release Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 23, 2024, titled New Drug Application of Zydus innovative drug Desidustat tablets by China Medical System Holdings Limited accepted in China. |
Mon, 22 Apr 2024 |
Closing Above Previous High |
Close Within 52 Week High Zone |
High Increase in 3 Months |
High Increase in 6 Months |
High Increase in 1 Year |